Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.